Gwenan M Knight1, Caroline Colijn2, Sourya Shrestha3, Mariam Fofana3, Frank Cobelens4, Richard G White1, David W Dowdy3, Ted Cohen5. 1. Tuberculosis Modelling Group, Centre for the Mathematical Modelling of Infectious Diseases, Tuberculosis Centre, Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Public Health, London School of Hygiene and Tropical Medicine. 2. Department of Mathematics, Imperial College London, United Kingdom. 3. Department of Epidemiology, Johns Hopkins School of Public Health, Baltimore, Maryland. 4. Amsterdam Institute for Global Health and Development, Academic Medical Center KNCV Tuberculosis Foundation, The Hague, The Netherlands. 5. Department of Epidemiology of Microbial Diseases, School of Public Health, Yale University, New Haven, Connecticut.
Abstract
BACKGROUND: Drug resistance poses a serious challenge for the control of tuberculosis in many settings. It is well established that the expected future trend in resistance depends on the reproductive fitness of drug-resistant Mycobacterium tuberculosis. However, the variability in fitness between strains with different resistance-conferring mutations has been largely ignored when making these predictions. METHODS: We developed a novel approach for incorporating the variable fitness costs of drug resistance-conferring mutations and for tracking this distribution of fitness costs over time within a transmission model. We used this approach to describe the effects of realistic fitness cost distributions on the future prevalence of drug-resistant tuberculosis. RESULTS: The shape of the distribution of fitness costs was a strong predictor of the long-term prevalence of resistance. While, as expected, lower average fitness costs of drug resistance-conferring mutations were associated with more severe epidemics of drug-resistant tuberculosis, fitness distributions with greater variance also led to higher levels of drug resistance. For example, compared to simulations in which the fitness cost of resistance was fixed, introducing a realistic amount of variance resulted in a 40% increase in prevalence of drug-resistant tuberculosis after 20 years. CONCLUSIONS: The differences in the fitness costs associated with drug resistance-conferring mutations are a key determinant of the future burden of drug-resistant tuberculosis. Future studies that can better establish the range of fitness costs associated with drug resistance-conferring mutations will improve projections and thus facilitate better public health planning efforts.
BACKGROUND: Drug resistance poses a serious challenge for the control of tuberculosis in many settings. It is well established that the expected future trend in resistance depends on the reproductive fitness of drug-resistant Mycobacterium tuberculosis. However, the variability in fitness between strains with different resistance-conferring mutations has been largely ignored when making these predictions. METHODS: We developed a novel approach for incorporating the variable fitness costs of drug resistance-conferring mutations and for tracking this distribution of fitness costs over time within a transmission model. We used this approach to describe the effects of realistic fitness cost distributions on the future prevalence of drug-resistant tuberculosis. RESULTS: The shape of the distribution of fitness costs was a strong predictor of the long-term prevalence of resistance. While, as expected, lower average fitness costs of drug resistance-conferring mutations were associated with more severe epidemics of drug-resistant tuberculosis, fitness distributions with greater variance also led to higher levels of drug resistance. For example, compared to simulations in which the fitness cost of resistance was fixed, introducing a realistic amount of variance resulted in a 40% increase in prevalence of drug-resistant tuberculosis after 20 years. CONCLUSIONS: The differences in the fitness costs associated with drug resistance-conferring mutations are a key determinant of the future burden of drug-resistant tuberculosis. Future studies that can better establish the range of fitness costs associated with drug resistance-conferring mutations will improve projections and thus facilitate better public health planning efforts.
Authors: Sebastien Gagneux; Clara Davis Long; Peter M Small; Tran Van; Gary K Schoolnik; Brendan J M Bohannan Journal: Science Date: 2006-06-30 Impact factor: 47.728
Authors: M de Vos; B Müller; S Borrell; P A Black; P D van Helden; R M Warren; S Gagneux; T C Victor Journal: Antimicrob Agents Chemother Date: 2012-12-03 Impact factor: 5.191
Authors: Yuri F van der Heijden; Fareed Abdullah; Bruno B Andrade; Jason R Andrews; Devasahayam J Christopher; Julio Croda; Heather Ewing; David W Haas; Mark Hatherill; C Robert Horsburgh; Vidya Mave; Helder I Nakaya; Valeria Rolla; Sudha Srinivasan; Retna Indah Sugiyono; Cesar Ugarte-Gil; Carol Hamilton Journal: Tuberculosis (Edinb) Date: 2018-10-01 Impact factor: 3.131
Authors: Palwasha Y Khan; Tom A Yates; Muhammad Osman; Robin M Warren; Yuri van der Heijden; Nesri Padayatchi; Edward A Nardell; David Moore; Barun Mathema; Neel Gandhi; Vegard Eldholm; Keertan Dheda; Anneke C Hesseling; Valerie Mizrahi; Roxana Rustomjee; Alexander Pym Journal: Lancet Infect Dis Date: 2018-12-13 Impact factor: 25.071
Authors: Willy Ssengooba; Conor J Meehan; Deus Lukoye; George William Kasule; Kenneth Musisi; Moses L Joloba; Frank G Cobelens; Bouke C de Jong Journal: Infect Genet Evol Date: 2016-02-23 Impact factor: 3.342
Authors: Emily A Kendall; Sourya Shrestha; Ted Cohen; Eric Nuermberger; Kelly E Dooley; Lice Gonzalez-Angulo; Gavin J Churchyard; Payam Nahid; Michael L Rich; Cathy Bansbach; Thomas Forissier; Christian Lienhardt; David W Dowdy Journal: PLoS Med Date: 2017-01-03 Impact factor: 11.069
Authors: Ariadna Rando-Segura; María Luisa Aznar; María Milagros Moreno; Mateu Espasa; Elena Sulleiro; Cristina Bocanegra; Eva Gil; Arlete N E Eugénio; Carlos Escartin; Adriano Zacarias; Josep Vegue; Domingos Katimba; María Carmen Vivas; Estevao Gabriel; María Concepción Marina; Jacobo Mendioroz; María Teresa López; Tomas Pumarola; Israel Molina; María Teresa Tórtola Journal: Emerg Infect Dis Date: 2018-03 Impact factor: 6.883
Authors: Gwenan M Knight; Mirko Zimic; Sebastian Funk; Robert H Gilman; Jon S Friedland; Louis Grandjean Journal: J R Soc Interface Date: 2018-06 Impact factor: 4.118
Authors: Deisy M G C Rocha; Carlos Magalhães; Baltazar Cá; Angelica Ramos; Teresa Carvalho; Iñaki Comas; João Tiago Guimarães; Helder Novais Bastos; Margarida Saraiva; Nuno S Osório Journal: Front Microbiol Date: 2021-06-11 Impact factor: 5.640
Authors: Phillip P Salvatore; Alvaro Proaño; Emily A Kendall; Robert H Gilman; David W Dowdy Journal: J Infect Dis Date: 2017-12-27 Impact factor: 5.226